SolAeroMed is a company dedicated to the development of novel therapeutic strategies to treat obstructive lung diseases. Our lead asthma drug is in Phase II clinical trials designed to demonstrate Proof of Concept.   SolAeroMed seeks a development partner(s) for our $4-$6 Billion lifetime sales market as a new class of asthma drug and delivery device. For more details please see our Business Presentation (Adobe PDF).